Skip to main
BFRI
BFRI logo

Biofrontera (BFRI) Stock Forecast & Price Target

Biofrontera (BFRI) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Biofrontera Inc is poised for potential revenue acceleration due to the anticipated market introduction of new indications for treatments targeting superficial Basal Cell Carcinoma and Actinic Keratoses in 2026 and 2027. The expansion of their salesforce, alongside favorable reimbursement strategies, is expected to enhance the competitive positioning of Ameluz against cryotherapy, ultimately converting more customers to photodynamic therapy. Additionally, historic sales patterns indicate that the fourth quarter will be critical for revenue growth, supported by revised labeling that allows for increased dosages of Ameluz per treatment session.

Bears say

Biofrontera's stock outlook is negatively impacted by its revenue performance, with reported revenue of $8.6 million falling short of both internal estimates of $10.6 million and consensus forecasts, indicating potential operational weaknesses. Additionally, there are concerns regarding regulatory uncertainties that could adversely affect revenue generation and increase operational costs. The anticipated trading valuation for Biofrontera has been significantly revised down to $2.75 per share from a previous target of $7, reflecting a lack of confidence in the company's ability to meet future expectations.

Biofrontera (BFRI) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biofrontera and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biofrontera (BFRI) Forecast

Analysts have given Biofrontera (BFRI) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Biofrontera (BFRI) has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biofrontera (BFRI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.